CYTK Cytokinetics Forecast, Technical & Fundamental Analysis
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining... Show more
CYTK is expected to report earnings to fall 3.33% to -145 cents per share on October 29
Q3'26
Est.
$-1.45
Q2'26
Beat
by $0.13
Q1'26
Missed
by $0.02
Q4'25
Beat
by $0.06
Q3'25
Missed
by $0.98
The last earnings report on August 06 showed earnings per share of -150 cents, beating the estimate of -162 cents. With 587.16K shares outstanding, the current market capitalization sits at 10.11B.
A.I. Advisor
published General Information
General Information
a company which engages in discovery and development of small molecule drug therapeutics
A.I.dvisor indicates that over the last year, CYTK has been loosely correlated with MLYS. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if CYTK jumps, then MLYS could also see price increases.
CYTK in upward trend: price may jump up because it broke its lower Bollinger Band on August 28, 2026
CYTK may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In of 42 cases where CYTK's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 68 cases where CYTK's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where CYTK advanced for three days, in of 293 cases, the price rose further within the following month. The odds of a continued upward trend are .
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on August 28, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CYTK as a result. In of 100 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for CYTK turned negative on August 28, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 57 similar instances when the indicator turned negative. In of the 57 cases the stock turned lower in the days that followed. This puts the odds of success at .
CYTK moved below its 50-day moving average on August 07, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for CYTK crossed bearishly below the 50-day moving average on August 10, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 23 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CYTK declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for CYTK entered a downward trend on September 04, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. CYTK’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CYTK’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock better than average.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (60.606) is normal, around the industry mean (20.363). P/E Ratio (0.000) is within average values for comparable stocks, (27.551). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.538). Dividend Yield (0.000) settles around the average of (0.018) among similar stocks. P/S Ratio (133.333) is also within normal values, averaging (445.402).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
